Z17.21
Progesterone receptor positive status
Clinical Classification Guidelines
Inclusion Terms
- PR+
Medical Intelligence & Overview
Progesterone receptor positive (PR+) status refers to the presence of hormone receptors for progesterone in certain cells, particularly in breast tissue or cancer cells. This condition is identified through laboratory testing and plays a key role in breast cancer diagnosis and treatment planning. A PR+ status indicates that cells have receptors that can bind to progesterone, a hormone involved in the menstrual cycle and pregnancy. The presence of these receptors often suggests that the growth of abnormal cells may be stimulated by hormones, which has implications for targeted therapies.
Causes & Symptoms
Clinical Causes: Hormonal Influences: Elevated levels of progesterone can stimulate the growth of cells that have progesterone receptors. Genetic Factors: Certain genetic mutations and inherited traits can influence receptor expression. Cancer Development: In breast cancer, PR+ status often develops as part of the tumor's biological characteristics. Receptor Expression Variability: Variations in gene expression can lead to either positive or negative receptor status.
Key Symptoms: Often, PR+ status is asymptomatic and discovered during routine screening or biopsy. If associated with breast cancer, symptoms may include a lump in the breast, changes in breast size or shape, skin changes, or nipple discharge. No specific symptoms directly indicate PR+ status; it is identified through laboratory analysis of tissue samples.
Diagnostic & Treatment
Diagnosis Path: - Reporting results as positive or negative, with a percentage indicating the proportion of cells with receptors.
Treatment Protocols: - Regular monitoring to evaluate treatment response and adjust as needed.
Clinical Advice & FAQs
Billing Guidance
Is Z17.21 a billable ICD-10 code?
Yes, Z17.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.21?
Clinical documentation must specify the nature of Progesterone receptor positive status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference